Despite a Buy-equivalent average brokerage recommendation (ABR of 2.00), the article advises caution. The Zacks Rank #3 (Hold) rating and unchanged consensus earnings estimate of $0.78 suggest the stock is expected to perform in line with the broader market rather than outperform, warranting a neutral stance.
ADMA Biologics news
About ADMA Biologics
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to artificially inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that caused investor losses.
The company is the subject of a securities fraud class action lawsuit alleging material misrepresentations about financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report exposed channel stuffing practices, resulting in a 31.6% stock price decline over two days, indicating severe loss of investor confidence and significant financial harm to shareholders.
Company is subject to securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock experienced significant declines (16% and 13%) following negative reports and analyst downgrades, indicating loss of investor confidence.
Company allegedly engaged in undisclosed related party transactions, used channel stuffing to artificially inflate revenue, lacked adequate internal controls, and made materially misleading statements about business prospects.
The company faces serious allegations of fraudulent business practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. These allegations resulted in a 29.1% stock price decline and triggered a securities fraud class action lawsuit, indicating significant investor harm and loss of confidence.
The company faces serious allegations of securities fraud including undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Stock price collapsed 31.6% following revelations, with additional 13.9% decline after analyst downgrade, indicating severe loss of investor confidence and substantial shareholder value destruction.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations suggest serious corporate governance failures and potential fraud, resulting in investor losses.
The company is accused of material financial misrepresentations, undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Stock experienced severe declines (31.6% combined over two days, followed by additional 13.9% drop) following corrective disclosures, resulting in substantial shareholder losses and triggering a class action lawsuit.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.
Company is facing securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following negative reports and analyst downgrades. The lawsuit alleges management made false and misleading statements about revenue growth.
Company is facing securities fraud allegations for channel stuffing scheme that artificially inflated revenue growth. Stock declined 29% following investigative report revelations, with multiple analyst downgrades. Investors are being encouraged to join class action lawsuit to recover losses.
Company faces securities fraud allegations involving financial misrepresentation, undisclosed related-party transactions, and channel stuffing. Stock experienced a severe 31.6% decline following exposure of these practices, with continued losses following management's response.
The company is facing serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to artificially inflate revenue, inadequate internal controls, and making materially false and misleading statements about its business operations. These are significant compliance violations that undermine investor confidence and indicate potential financial and operational misconduct.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and financial reporting violations that caused investor damages.
The company faces a securities fraud class action lawsuit alleging material misrepresentations about financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report exposed channel stuffing practices, resulting in a severe 31.6% stock price decline over two trading days and additional losses following a company response and analyst downgrade.
The company faces serious allegations of fraudulent accounting practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. A short report triggered a 16.63% stock price decline, and a class action lawsuit has been filed against the company, indicating significant legal and financial risks.
The company faces a securities fraud class action alleging material misrepresentations regarding financial condition, revenue recognition, and business practices. A short-seller report exposed alleged channel stuffing and undisclosed related-party transactions, resulting in a 31.6% stock price decline over two days and further losses following management's response and analyst downgrades.
Company is subject to class action lawsuit alleging securities fraud and channel stuffing scheme. Stock price fell 16.63% on March 24 and an additional 13.91% on March 26 following short report allegations and analyst downgrade citing inadequate response to fraud allegations.
The company faces serious allegations of financial fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% then 13%) following damaging reports, and a major analyst downgraded the stock from Overweight to Neutral, indicating loss of investor confidence.
Defendants allegedly engaged in undisclosed related party transactions, channel stuffing, lacked adequate internal controls, and made misleading statements about business operations.
The company is the subject of a securities fraud class action lawsuit alleging undisclosed related party transactions, channel stuffing to inflate revenue, inadequate internal controls, and materially false statements about business operations and prospects.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations suggest serious corporate governance and financial reporting issues that resulted in investor losses.
Company faces securities fraud allegations for channel stuffing scheme that artificially inflated reported revenue growth. Stock declined 29% following investigative report revealing actual revenue decline of 3% versus reported 20% growth. Class action lawsuit filed with significant investor losses.
Company is facing securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following negative reports and analyst downgrades. The lawsuit alleges material misstatements about revenue growth.
The company is accused of material securities fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. The stock experienced a 29% decline following the investigative report, and the company faces significant legal liability and reputational damage from the class action lawsuit.
Company faces shareholder class action lawsuit alleging materially false statements and failure to disclose material facts regarding business and financial practices between August 2024 and March 2026.
Company is subject to securities fraud allegations involving material misstatements about revenues, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Stock price fell 29.1% following disclosure of these issues.
Company faces securities fraud allegations involving channel stuffing and undisclosed related party transactions. Stock price declined approximately 46% following short seller report exposure (from $13.59 to $8.29 over three days). Analyst downgrade from Cantor Fitzgerald and investor concerns about cash flow inconsistencies further support negative sentiment.
The company faces serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to inflate revenues, and inadequate internal controls. Stock price declined significantly (16% then 13%) following negative reports and analyst downgrades, indicating loss of investor confidence.
The company faces serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to artificially inflate revenues, and inadequate internal controls. The stock experienced a significant 29.1% decline following the disclosure of these issues, indicating substantial investor losses and loss of confidence in the company's financial reporting.
The company faces serious allegations of financial fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following the short-seller report and analyst downgrade, indicating loss of investor confidence.
The company is accused of securities fraud, including making false and misleading statements, undisclosed related party transactions, revenue manipulation through channel stuffing, and inadequate internal controls. These serious allegations resulted in investor losses and triggered a class action lawsuit.
The company faces serious allegations of fraudulent accounting practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. A short report triggered a 16.63% stock price decline, and a class action lawsuit has been filed against the company, indicating significant legal and reputational risks.
The company faces serious allegations of material misstatements, undisclosed related party transactions, channel stuffing to artificially inflate revenues, and inadequate internal controls. The stock experienced a significant 29.1% decline following exposure of these practices, indicating substantial investor losses and loss of confidence.
The company faces serious allegations of misleading investors through undisclosed related party transactions, channel stuffing, and inadequate internal controls. The stock experienced significant declines (31.6% total over two days) following the exposure of these issues, indicating loss of investor confidence and potential material misstatements in financial reporting.
The company faces serious allegations of fraudulent accounting practices including channel stuffing and undisclosed related party transactions. The stock experienced a significant 29.1% decline following these revelations, and a class action lawsuit has been filed alleging materially false statements about business performance and inadequate internal controls.
The company faces serious allegations of securities fraud including channel stuffing, undisclosed related party transactions, and artificially inflated revenues. A class action lawsuit has been filed, and the stock experienced a significant 29.1% decline following the fraud allegations, indicating substantial investor losses and reputational damage.
Also mentions ADMA
Articles that tag ADMA but are mainly about other companies.
Company is subject to an ongoing securities class action lawsuit with an imminent lead plaintiff deadline, indicating alleged investor harm and potential securities violations.
Company is subject to a securities fraud class action lawsuit with an August 10, 2026 application deadline for lead plaintiffs, indicating alleged material misstatements or omissions.
Company faces a securities class action lawsuit first filed by Rosen Law Firm with an August 10 deadline for lead plaintiff claims, suggesting alleged securities fraud or misrepresentation.
ADMA Biologics is subject to a shareholder class action lawsuit alleging false and/or misleading statements made by the company and its executives to investors, with an August 10, 2026 deadline for lead plaintiff appointment.
A new class action lawsuit has been filed alleging securities fraud violations with a lead plaintiff deadline of 8/10/2026.
Subject of a securities class action lawsuit first filed by Rosen Law Firm, indicating alleged investor harm and potential securities violations.
Company is subject to ongoing securities investigation by Rosen Law Firm for potential shareholder claims, indicating alleged securities violations or investor losses.
Company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, indicating alleged shareholder harm.
Mentioned as B Group's top holding (21.4% of AUM) but no specific news or developments are discussed in the article. Inclusion is purely informational regarding fund composition.
Company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, suggesting alleged violations of securities laws.
The company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, indicating alleged violations that may have caused investor losses.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology